Israel’s Pi Therapeutics (PiTx) is developing a treatment for PI-resistant Multiple Myeloma (MM) and solid tumors. Its small molecule non-catalytic UPS inhibitors have worked in lab tests. MM is an incurable blood cancer. PiTx has just raised $19.7 million for a formal clinical proof of concept.
https://www.calcalistech.com/ctech/articles/0,7340,L-3763205,00.html